Effect of the Novel Myotrope Danicamtiv on Cross‐Bridge Behavior in Human Myocardium
Journal of the American Heart Association · 2023
DOI: 10.1161/jaha.123.030682 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Joohee Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biophysics, School of Medicine Case Western Reserve University Cleveland OH. Hauptthemen laut MEDLINE: Myocardial Contraction, Myocardium. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Omecamtiv mecarbil (OM) and danicamtiv both increase myocardial force output by selectively activating myosin within the cardiac sarcomere. Enhanced force generation is presumably due to an increase in the total number of myosin heads bound to the actin filament; however, detailed comparisons of the molecular mechanisms of OM and danicamtiv are lacking. Methods and Results The effect of OM and danicamtiv on Ca 2+ sensitivity of force generation was analyzed by exposing chemically skinned myocardial samples to a series of increasing Ca 2+ solutions. The results showed that OM significantly increased Ca 2+ sensitivity of force generation, whereas danicamtiv showed similar Ca 2+ sensitivity of force generation to untreated preparations. A direct comparison of OM and danicamtiv on dynamic cross‐bridge behavior was performed at a concentration that produced a similar force increase when normalized to predrug levels at submaximal force (pCa 6.1). Both OM and danicamtiv‐treated groups slowed the rates of cross‐bridge detachment from the strongly bound state and cross‐bridge recruitment into the force‐producing state. Notably, the significant OM‐induced prolongation in the time to reach force relaxation and subsequent commencement of force generation following rapid stretch was dramatically reduced in danicamtiv‐treated myocardium.
Conclusions
This is the first study to directly compare the effects of OM and danicamtiv on cross‐bridge kinetics. At a similar level of force enhancement, danicamtiv had a less pronounced effect on the slowing of cross‐bridge kinetics and, therefore, may provide a similar improvement in systolic function as OM without excessively prolonging systolic ejection time and slowing cardiac relaxation facilitating diastolic filling at the whole‐organ level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Biophysics, School of Medicine Case Western Reserve University Cleveland OH.
- Division of Cardiovascular Medicine University of Kentucky Lexington KY.
- Department of Physiology University of Kentucky Lexington KY.
ORCID-Profile: Joohee Choi, Joshua B Holmes, Kenneth S Campbell, Julian E Stelzer
Förderung
- NHLBI NIH HHS
Zitieren
APA
Choi, J., Holmes, J. B., Campbell, K. S., & Stelzer, J. E. (2023). Effect of the Novel Myotrope Danicamtiv on Cross‐Bridge Behavior in Human Myocardium. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.030682
Vancouver
Choi J, Holmes JB, Campbell KS, Stelzer JE. Effect of the Novel Myotrope Danicamtiv on Cross‐Bridge Behavior in Human Myocardium. Journal of the American Heart Association. 2023. doi:10.1161/jaha.123.030682
BibTeX
@article{Choi2023,
author = {Choi, Joohee and Holmes, Joshua B and Campbell, Kenneth S and Stelzer, Julian E},
title = {Effect of the Novel Myotrope Danicamtiv on Cross‐Bridge Behavior in Human Myocardium},
journal = {Journal of the American Heart Association},
year = {2023},
doi = {10.1161/jaha.123.030682}
}
EUVIMED